8-K: Vaxart Shares Delisted from Nasdaq, Begin Trading on OTCQX Best Market Amid Appeal

Vaxart, Inc. announced its common stock was delisted from The Nasdaq Capital Market due to non-compliance with the minimum bid price requirement and has commenced trading on the OTCQX Best Market while the company appeals Nasdaq's decision.

Summary

• Vaxart, Inc.'s common stock was delisted from The Nasdaq Capital Market at the open of trading on July 8, 2025.
• The delisting resulted from the company's ongoing failure to comply with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.
• Since July 8, 2025, Vaxart's common stock has traded on the OTCQX Best Market of the OTC Markets Group under its existing ticker symbol VXRT.
• Vaxart appealed Nasdaq's delisting determination on July 3, 2025, and its common stock remains suspended on Nasdaq pending a decision from the Nasdaq Hearings Panel.
• The company is a clinical-stage biotechnology firm developing oral recombinant pill vaccines for infectious diseases like coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).

Sentiment

Score: 3

Explanation: The delisting from Nasdaq due to minimum bid price non-compliance is a significant negative event, indicating financial distress or lack of investor confidence. While trading continues on OTCQX and an appeal is underway, the immediate impact is negative for shareholders and the company's market standing.

Positives

• Vaxart's common stock has been approved to trade on the OTCQX Best Market, providing continued market access for shareholders.
• The OTCQX Market is the highest tier of OTC Markets Group, offering greater transparency, visibility, and accessibility to investors within the OTC Markets.
• The company is actively appealing Nasdaq's delisting decision, indicating efforts to regain a Nasdaq listing.
• Management reiterated its focus on strengthening Vaxart by advancing the development of its proprietary oral pill vaccines.

Negatives

• Vaxart's common stock was delisted from The Nasdaq Capital Market.
• The delisting was due to the company's failure to comply with Nasdaq's minimum bid price requirement.
• Trading in the company's common stock on Nasdaq was suspended.

Risks

• Consequences of the Delisting Notice.
• Results of the company's appeal to the Nasdaq Hearings Panel.
• The company's ability to regain compliance with the Minimum Bid Price Requirement.
• Continuing operating losses.
• Uncertainty of market acceptance for its products.
• Reliance on third-party manufacturers.
• Accumulated deficit.
• Future capital needs and uncertainty of capital funding.
• Dependence on a limited product line and distribution channels.
• Competition within the biotechnology and vaccine development industry.
• Limited marketing and manufacturing experience.

Future Outlook

Vaxart is considering all options regarding its stock listing, prioritizing shareholder interests, while maintaining its primary focus on strengthening the company by advancing the development of its proprietary oral pill vaccines designed to address infectious diseases.

Management Comments

• "We are considering all options regarding our stock listing, keeping our shareholders best interests in mind. At the same time, our focus will remain on strengthening Vaxart by advancing the development of our proprietary oral pill vaccines, which are engineered to address infectious diseases."

Industry Context

The delisting of a biotechnology company from a major exchange like Nasdaq to the OTCQX market is a significant event, often signaling challenges in maintaining investor confidence and meeting listing requirements. For clinical-stage biotech companies, access to capital and visibility on major exchanges are crucial for funding research and development. While OTCQX offers a regulated trading environment, it typically has lower liquidity and less institutional investor participation compared to Nasdaq, which can impact a company's ability to raise capital and its valuation. This move highlights the ongoing financial pressures and regulatory hurdles faced by smaller biotech firms as they progress through costly development cycles.

Legal Proceedings

• Appeal of Nasdaq's delisting determination to the Nasdaq Hearings Panel pursuant to Nasdaq Listing Rule 5800 Series.

Stakeholder Impact

• Shareholders: Trading venue changed from Nasdaq to OTCQX, potentially impacting liquidity and investor perception. Shares remain suspended on Nasdaq during the appeal.
• Employees: Management's continued focus on advancing vaccine development suggests ongoing operational stability and commitment to the company's core mission.
• Investors: The move to OTCQX may affect institutional investment and overall market visibility.

Next Steps

• Decision from the Nasdaq Hearings Panel regarding Vaxart's appeal.
• Continued development of proprietary oral pill vaccines, including programs for coronavirus, norovirus, influenza, and HPV.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, Nasdaq delisting, OTCQX Best Market, oral vaccines, biotechnology, clinical-stage, minimum bid price, SEC filing, 8-K, vaccine development, infectious diseases